A new treatment option for Alzheimer's is now available — John G. Baresky The FDA has approved Biogen’s (NASDAQ: BIIB) Aduhelm (aducanumab) for the treatment of Alzheimer’s disease, giving patients and medical professionals a desperately needed treatment option of which there are very few. Biogen developed the drug in collaboration with Tokyo, Japan-based Eisai, Co. (OTCMKTS: ESALY). It has been…